共 199 条
[1]
Furugohri T(2008)DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles J Thromb Haemost 6 1542-1549
[2]
Isobe K(2010)Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study Thromb Haemost 104 642-649
[3]
Honda Y(2010)Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb Haemost 104 633-641
[4]
Kamisato-Matsumoto C(2010)Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 635-641
[5]
Sugiyama N(2013)Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2093-2104
[6]
Nagahara T(2013)Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 1406-1415
[7]
Morishima Y(2013)Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects Clin Pharmacol Drug Dev 2 358-366
[8]
Shibano T(2010)Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 743-753
[9]
Raskob G(2012)Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans Drug Metab Dispos 40 2250-2255
[10]
Cohen AT(2013)Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment Clin Pharmacokinet 52 243-254